Specialty chemical supplier AlzChem AG postpones planned IPO
Trostberg, February 7, 2017 – AlzChem AG (together with its subsidiaries hereinafter “AlzChem”), a vertically integrated specialty chemicals producer with a leading market position in selected niche markets, is postponing its planned IPO. The first day of trading of the shares of AlzChem AG in the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange was initially planned for February 10, 2017.
Although index levels are relatively high at the moment, the market environment currently dominated by political issues caused persistent uncertainty when it comes to making new investments. Despite significant institutional investor interest in Europe and the USA, a placement within the aspired price range was therefore ultimately not possible.
Ulli Seibel, CEO of AlzChem AG, comments: “We want to thank the investors who have subscribed as well as those who have analyzed the company. Special thanks also go to our employees, consultants and banking teams who worked with great commitment on the IPO. Even without an IPO in the near future, we will continue on our growth path and invest in the further development of our Specialty Chemicals business segment. We will now make use of alternative financing options for this purpose.”
Chemicals business segment. We will now make use of alternative financing options for this purpose.”
AlzChem will re-evaluate the possibility of an IPO at some stage in the future. The company has a high internal financing capability and is well-positioned with its high-margin Specialty Chemical products to benefit from external growth drivers such as global population growth, the healthy aging trend and the growing importance of energy efficiency.
About AlzChem AG
AlzChem AG, located in Trostberg, Bavaria, is a vertically integrated manufacturer of various chemical products based on the NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding, which are used in a variety of industries. The company has a leading market position in selected niche markets, including the markets for feed additives and food supplements. The strategic focus of growth and the focus of the extensive research and development lie on the business segment Specialty Chemicals. The joint production and the brand portfolio protect AlzChem from potential market entries. The company has 1,480 employees at four sites in Germany and three others abroad.
Investor Relations Contact
Henryk Deter / Maximilian Breuer
Tel.: +49 (0)611 - 205855-22
Fax: +49 (0)611 - 205855-66
This publication may not be published, distributed or transmitted, directly or indirectly, in or into the United States, Canada, Japan or Australia. This publication constitutes neither an offer to sell nor an invitation to buy or subscribe securities in the United States or Germany or any other jurisdiction. The shares in AlzChem AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the Securities Act of 1933, as amended (the “Securities Act”)) absent registration or an exemption from registration under the Securities Act. The Shares have not been and will not be registered under the Securities Act. No offer or sale of securities is being made to the public outside Germany or Luxembourg. The offers in Germany and Luxembourg will be made exclusively by means of and on the basis of a prospectus published and available free of charge at www.alzchem.com.
This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.